author-photo

Lone H. Ottesen

GlaxoSmithKline

24

Papers

788

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

Abstract 591: Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (30)
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

2015 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (8)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (336)
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

2013 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (12)
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib

2013 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (8)
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)